Source: Pharmacy Times articles
Data from a phase 1b study showed significantly reduced toxicity compared with conventional oral dosing.
Recent Content
- What Should Patients with Multiple Myeloma Know After ASCO 2025?
- Continuous Subcutaneous Lenalidomide Shows Promise in Reducing Toxicity in R/R Multiple Myeloma
- Traveling with Multiple Myeloma: A Journey of Adaptation and Hope
- Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
- Pharmacists Reimagine Myeloma Care With Insights from ASCO
- A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM)
- High Response Rates With Talquetamab Plus Teclistamab in Triple-Class Refractory Multiple Myeloma
- Efficacy and safety of anti-CD38 monoclonal antibodies in patients with newly diagnosed multiple myeloma: an updated systematic review and meta-analysis based on randomized controlled trials
- Author Correction: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes
- You Are Not Alone While Building a Support Team During Cancer Care